ATE321045T1 - Methoden und zusammensetzungen zur behandlung von schmerzen - Google Patents
Methoden und zusammensetzungen zur behandlung von schmerzenInfo
- Publication number
- ATE321045T1 ATE321045T1 AT00987932T AT00987932T ATE321045T1 AT E321045 T1 ATE321045 T1 AT E321045T1 AT 00987932 T AT00987932 T AT 00987932T AT 00987932 T AT00987932 T AT 00987932T AT E321045 T1 ATE321045 T1 AT E321045T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- treating pain
- pain
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17190699P | 1999-12-23 | 1999-12-23 | |
US23688100P | 2000-09-29 | 2000-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE321045T1 true ATE321045T1 (de) | 2006-04-15 |
Family
ID=26867561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00987932T ATE321045T1 (de) | 1999-12-23 | 2000-12-19 | Methoden und zusammensetzungen zur behandlung von schmerzen |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030181449A1 (de) |
EP (1) | EP1244660B1 (de) |
JP (1) | JP2003519146A (de) |
AT (1) | ATE321045T1 (de) |
AU (1) | AU2420001A (de) |
DE (1) | DE60026883T2 (de) |
WO (1) | WO2001047924A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1325002B1 (de) * | 2000-09-29 | 2006-05-24 | AstraZeneca AB | 1,2,5,10-tetrahydropyridazino¬4,5-b|chinolin-1,10-dione und ihre anwendung in der behandlung von schmerzen |
EP1325005A1 (de) * | 2000-09-29 | 2003-07-09 | AstraZeneca AB | 1,2,5,10-tetrahydropyridazino-[4,5-b]chinolin-1,10-dione und ihre anwendung zur behandlung von schmerzen |
WO2002026741A1 (en) * | 2000-09-29 | 2002-04-04 | Astrazeneca Ab | 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
SE0403172D0 (sv) * | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | Manufacturing process |
DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
PT2408750E (pt) | 2009-03-20 | 2015-10-15 | Vertex Pharma | Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística |
EP2819670A1 (de) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmazeutische zusammensetzung und verabreichung davon |
RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
CA2892895A1 (en) * | 2015-05-28 | 2016-11-28 | Fluid Energy Group Ltd. | Novel organic acid compositions for use in the oil and gas industry |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
GB9420590D0 (en) * | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
US6787547B2 (en) * | 1999-12-23 | 2004-09-07 | Astrazeneca Ab | Compound and method for the treatment of pain |
-
2000
- 2000-12-19 DE DE60026883T patent/DE60026883T2/de not_active Expired - Fee Related
- 2000-12-19 AT AT00987932T patent/ATE321045T1/de not_active IP Right Cessation
- 2000-12-19 US US10/168,761 patent/US20030181449A1/en not_active Abandoned
- 2000-12-19 WO PCT/SE2000/002607 patent/WO2001047924A1/en active IP Right Grant
- 2000-12-19 EP EP00987932A patent/EP1244660B1/de not_active Expired - Lifetime
- 2000-12-19 AU AU24200/01A patent/AU2420001A/en not_active Abandoned
- 2000-12-19 JP JP2001549394A patent/JP2003519146A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2001047924A1 (en) | 2001-07-05 |
US20030181449A1 (en) | 2003-09-25 |
AU2420001A (en) | 2001-07-09 |
DE60026883T2 (de) | 2006-11-23 |
JP2003519146A (ja) | 2003-06-17 |
DE60026883D1 (de) | 2006-05-11 |
EP1244660A1 (de) | 2002-10-02 |
EP1244660B1 (de) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE250576T1 (de) | Substituierte pyrrolylverbindungen zur behandlung von entzündungen | |
ATE334985T1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
BG106825A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
EP1428821A8 (de) | Piperidin-4-ylamine mit analgetischer Wirksamkeit | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
SE9900961D0 (sv) | Novel compounds | |
SE0104248D0 (sv) | Method of treatment | |
ATE515253T1 (de) | Zusammensetzungen auf basis von etyllinoleat und triethylcitrat zur behandlung von seborrhöe und akne | |
ATE336997T1 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
DE60026883D1 (de) | Methoden und zusammensetzungen zur behandlung von schmerzen | |
ATE55695T1 (de) | Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien. | |
ATE323693T1 (de) | Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen | |
ATE172117T1 (de) | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE60013326D1 (de) | Verbindungen und verfahren zur behandlung von schmerz | |
ATE322244T1 (de) | Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen | |
ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
ATE297739T1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
NO982863L (no) | Nye forbindelser med analgetisk effekt | |
DE60030300D1 (de) | Topische behandlung zur vorbeugung von augeninfektionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |